TC
LJPC

TFS Capital’s La Jolla Pharmaceutical Company LJPC Stock Holding History

TFS Capital’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13,462
Closed -$248K – 1333
2014
Q4 		$248K Sell
13,462
-5,324
-28% -$63.2K 0.02% 774
2014
Q3 		$181K Buy
+18,786
New +$187K 0.02% 896

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TFS Capital's LJPC Position: Q1 2015 in Review

TFS Capital sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2015, closing a stake of 13,462 shares — an estimated $248K sold.

TFS Capital first reported a position in LJPC in Q3 2014 and held it in 2 quarters. The position peaked at $248K in Q4 2014. 40 funds tracked by Wall St. Rank hold LJPC as of Q1 2015.

  • TFS Capital reported no remaining La Jolla Pharmaceutical Company position as of Q1 2015 after selling out during the quarter.
  • TFS Capital sold 13,462 La Jolla Pharmaceutical Company shares in Q1 2015, an estimated $248K.
  • TFS Capital first reported a position in La Jolla Pharmaceutical Company in Q3 2014 and held it in 2 quarters.
  • TFS Capital's La Jolla Pharmaceutical Company position peaked at $248K in Q4 2014.
  • 40 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2015.

Based on TFS Capital's 13F filing for Q1 2015, filed 29 Apr 2015.